CRISPR Therapeutics AG Quarterly Debt-to-equity in % from Q2 2017 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
CRISPR Therapeutics AG quarterly Debt-to-equity history and growth rate from Q2 2017 to Q2 2024.
  • CRISPR Therapeutics AG Debt-to-equity for the quarter ending June 30, 2024 was 18.5 %, a 9.76% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 18.5 -2 -9.76% Jun 30, 2024
Q1 2024 19.2 -0.47 -2.39% Mar 31, 2024
Q4 2023 20.3 +1.89 +10.3% Dec 31, 2023
Q3 2023 20.6 +3.48 +20.4% Sep 30, 2023
Q2 2023 20.5 +5.41 +35.9% Jun 30, 2023
Q1 2023 19.7 +6.16 +45.6% Mar 31, 2023
Q4 2022 18.4 +6.48 +54.5% Dec 31, 2022
Q3 2022 17.1 +6.37 +59.4% Sep 30, 2022
Q2 2022 15.1 +4.92 +48.4% Jun 30, 2022
Q1 2022 13.5 +3.13 +30.2% Mar 31, 2022
Q4 2021 11.9 +0.19 +1.62% Dec 31, 2021
Q3 2021 10.7 -2.17 -16.8% Sep 30, 2021
Q2 2021 10.2 -5.26 -34.1% Jun 30, 2021
Q1 2021 10.4 -7.72 -42.7% Mar 31, 2021
Q4 2020 11.7 -10.3 -46.7% Dec 31, 2020
Q3 2020 12.9 -14.3 -52.5% Sep 30, 2020
Q2 2020 15.4 -13 -45.8% Jun 30, 2020
Q1 2020 18.1 -9.72 -35% Mar 31, 2020
Q4 2019 22 -5.17 -19% Dec 31, 2019
Q3 2019 27.2 -3.62 -11.8% Sep 30, 2019
Q2 2019 28.5 -10.5 -26.9% Jun 30, 2019
Q1 2019 27.8 -16.4 -37.1% Mar 31, 2019
Q4 2018 27.1 -24.3 -47.2% Dec 31, 2018
Q3 2018 30.8 -21.3 -40.9% Sep 30, 2018
Q2 2018 38.9 -43.7 -52.9% Jun 30, 2018
Q1 2018 44.2 Mar 31, 2018
Q4 2017 51.5 Dec 31, 2017
Q3 2017 52.1 Sep 30, 2017
Q2 2017 82.6 Jun 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.